SDS

Page 2/9
Safety Data Sheet
Regulation (EC) No. 1907/2006 and 1272/2008
Printing date 31.07.2018 Revision: 31.07.2018Version number 1
Trade name: SJ10W-30 GASOLINE ENGINE OIL
(Contd. of page 1)
47.0.4
·
Hazard-determining components of labelling:
Petroleum
·
Hazard statements
H319 Causes serious eye irritation.
H350 May cause cancer.
H412 Harmful to aquatic life with long lasting effects.
·
Precautionary statements
P273 Avoid release to the environment.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if
present and easy to do. Continue rinsing.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P405 Store locked up.
P501 Dispose of contents/container in accordance with local/regional/national/international
regulations.
·
Additional information:
Restricted to professional users.
·
2.3 Other hazards:
·
Results of PBT and vPvB assessment
·
PBT:
Not applicable.
·
vPvB:
Not applicable.
SECTION 3: Composition/information on ingredients
·
3.2 Mixtures
·
Description:
Mixture of the substances listed below with nonhazardous additions.
For the wording of the listed hazard statements refer to section 16.
·
Composition:
CAS: 8002-05-9
EINECS: 232-298-5
Index number: 649-049-00-5
Petroleum
Carc. 1B, H350
96.699%
CAS: 26264-06-2
EINECS: 247-557-8
Calcium dodecylbenzenesulphonate
Eye Dam. 1, H318; Skin Irrit. 2, H315
2.5%
CAS: 128-37-0
EINECS: 204-881-4
2,6-di-tert-butyl-p-cresol
Aquatic Acute 1, H400; Aquatic Chronic 1, H410
0.8%
CAS: 63148-62-9 Dimethyl siloxane 0.001%
SECTION 4: First aid measures
·
4.1 Description of first aid measures
·
After inhalation:
Supply fresh air; consult doctor in case of complaints.
·
After skin contact:
Generally the product does not irritate the skin.
·
After eye contact:
Rinse opened eye for several minutes under running water. If symptoms persist, consult a doctor.
·
After swallowing:
If symptoms persist consult doctor.
·
4.2 Most important symptoms and effects, both acute and delayed:
No further relevant information available.
·
4.3 Indication of any immediate medical attention and special treatment needed:
No further relevant information available.
EU
(Contd. on page 3)